This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Bicuspid Aortic Valve (Congenital Aortic Insufficiency)이첨대동맥판막

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q23.1 | Special Copayment Reduction: V147 (rare disease)
B. SynonymsBicuspid aortic valve | Congenital aortic valve insufficiency | Congenital insufficiency of the aortic valve | Congenital aortic regurgitation
C. Adult onsetPossibility of first onset in adulthood intermediate — bicuspid aortic valve (BAV) is the most common congenital heart malformation, occurring in 1–2% of births, but because there is often no obvious stenosis or regurgitation at birth, a high proportion are first diagnosed in adulthood on routine checkups or because of a heart murmur. When aortic valve insufficiency is the main pathology, an asymptomatic latent period of decades is common.
1. HistoryA research history running from Vesalius's anatomical description in 1543 and Peacock's classification of malformed valves in 1858 to the discovery of NOTCH1 (2005).
2. CausesFusion of aortic valve commissures in fetal life (mainly the right–left commissure); NOTCH1 and GATA5 abnormalities; multifactorial inheritance.
3. GeneticsNOTCH1 (9q34.3) central; GATA5, NKX2.5, ROBO4 additional related genes; autosomal dominant (incomplete penetrance).
4. General epidemiology1–2% of births, male-to-female ratio about 3:1; the most common isolated malformation among congenital heart malformations; more than about 100 million people worldwide.
5. PathophysiologyIncomplete valve closure (regurgitation) → left ventricular volume overload → eccentric hypertrophy → impaired diastolic function → impaired systolic function.
6. SymptomsOften asymptomatic in childhood; exercise intolerance, dyspnea, and fatigue progress gradually in adulthood; pulmonary edema in acute regurgitation.
7. SignsDiastolic regurgitant murmur (left sternal border), widened pulse pressure, water hammer pulse (Corrigan pulse), de Musset sign, Austin Flint murmur.
8. ScreeningEchocardiography of first-degree relatives of BAV patients; screening for aortopathy (CT/MRI); cardiac evaluation before pregnancy.
9. DiagnosisEchocardiography (Doppler grading of regurgitation); CMR for precise calculation of volumes and regurgitant fraction; aortic CT/MRI for evaluation of aortopathy.
10. TreatmentAsymptomatic moderate to severe: regular follow-up; severe regurgitation + symptoms or LV dysfunction or EDD >70mm: valve surgery.
11. PrognosisExcellent long-term survival after modern surgery; aortopathy, endocarditis, and reoperation are the main long-term risk factors.
12. PreventionPrevention of endocarditis; screening of BAV families; regular echocardiography and aortic imaging; blood pressure control; prior evaluation when planning pregnancy.
13. References10 major clinical guidelines and original papers

1. History

Bicuspid aortic valve (BAV) is one of the oldest congenital heart malformations recorded by humankind. Variations of the aortic valve are thought to have already been mentioned in Andreas Vesalius's great anatomical work (De Humani Corporis Fabrica) of 1543, and European anatomists of the 17th–18th centuries repeatedly described aortic valves with a bicuspid structure at autopsy. In 1858, Peacock established the bicuspid aortic valve as an independent malformation while systematically classifying congenital heart malformations.

In the 20th century, the clinical importance of BAV came to the fore. In 1928, Maude Abbott reported from a database of 1,000 cases of congenital heart malformations that BAV had the highest frequency among all congenital heart malformations. The advent of echocardiography in the 1970s made noninvasive diagnosis possible, and the spread of Doppler echocardiography in the 1980s–90s made quantification of aortic regurgitation and stenosis possible. In the 1990s, it began to be shown that ascending aortic dilation (aortopathy) in BAV patients is due not simply to hemodynamic consequences but to an independent medial abnormality.

A landmark turning point in molecular genetic understanding was the 2005 report in Science by Garg et al. that NOTCH1 loss-of-function variants are associated with familial BAV and aortic valve calcification. Subsequently, additional genes such as GATA5, NKX2.5, and ROBO4 have been discovered, and the genetic heterogeneity of BAV is being elucidated. In Korea, the prevalence of BAV gradually began to be understood with the spread of adult echocardiographic screening after the 1990s, and systematic management is now provided through the Special Copayment Reduction (V147) system.


2. Causes

Bicuspid aortic valve (BAV) is a structural abnormality in which, during fetal development of the aortic valve, the commissure between two of the three semilunar cusps fuses, so that effectively only two cusps are formed. The most common fusion type is right-left cusp fusion (about 70–80%), followed by right-noncoronary fusion (about 20–25%) and left-noncoronary fusion (about 1–2%). The fusion type is associated with the form of aortopathy (ascending aortic dilation vs aortic arch dilation).

Embryologically, abnormal migration and remodeling of cardiac neural crest cells and second heart field cells are the key mechanism. The NOTCH1 signaling pathway plays a central role in the differentiation and maturation of valve endothelial cells and in suppressing abnormal calcification, and NOTCH1 loss-of-function variants cause BAV and aortic valve calcification. GATA5 abnormalities cause abnormal right coronary artery development and valve maturation, and NKX2.5 variants sometimes cause atrial septal defect together with BAV.

In congenital aortic valve insufficiency (regurgitation), incomplete closure due to size mismatch between the two cusps of the BAV structure, or cusp prolapse, causes regurgitation. In addition, enlargement of the valve annulus due to ascending aortic dilation worsens secondary regurgitation. Acute regurgitation due to valve destruction after infective endocarditis is also common in BAV patients.


3. Genetics

The genetic basis of BAV is multifactorial, and genetic heterogeneity is prominent. According to familial clustering studies, the incidence of BAV in first-degree relatives of BAV patients reaches 5–10 times that of the general population (1–2%), and the current mainstream view is a model of autosomal dominant inheritance with incomplete penetrance and variable expressivity.

NOTCH1 (9q34.3): since the report by Garg et al. in 2005, variants in this gene have been established as one of the key causes of BAV and aortic valve calcification. NOTCH1 is involved in regulating endothelial-to-mesenchymal transition (EndoMT) of valve endothelial cells and in suppressing calcification through the BMP/RUNX2 pathway. NOTCH1 variants are identified in only about 4–10% of all BAV patients. GATA5 (20q13.33): involved in valve maturation and right coronary artery development; in mouse models, GATA5 deletion causes BAV and ventricular septal defect. NKX2.5 (5q35.1): a pan-cardiac developmental transcription factor; variants cause BAV accompanied by atrial septal defect and atrioventricular conduction disturbances. ROBO4: involved in vascular endothelial cell development, and an association with BAV has been reported. In Turner syndrome (45,X), the frequency of BAV reaches 30–50%, reflecting the effect of X chromosome monosomy on cardiovascular development. Clinically, echocardiographic screening of first-degree relatives of BAV patients is strongly recommended.


4. General epidemiology

Bicuspid aortic valve (BAV) is the most common congenital heart malformation, occurring in about 1–2% of births. The prevalent population worldwide is estimated at about 100–150 million. It is more common in males, with a male-to-female ratio of about 2.5–3:1.

Q23.1 refers to bicuspid aortic valve in which aortic valve insufficiency (regurgitation) is the main pathology, distinguished from cases in which stenosis (Q23.0) is the main pathology. In practice, BAV progresses with growth to stenosis, regurgitation, or a mixed form, so the classification code for the same patient may change over the course of the disease.

Epidemiology of complications: about 25–50% of BAV patients undergo some form of cardiovascular intervention (valve intervention or aortic surgery) during their lifetime. Progression to aortic stenosis: significant stenosis develops in 30% of BAV patients before age 40–50 and in 60% before age 65. Ascending aortic dilation (aortopathy): present in 50–70% of BAV patients, with a risk of aortic dissection and rupture 5–9 times higher than in the general population.

Situation in Korea: according to Health Insurance Review & Assessment Service (HIRA) data, the annual number of outpatient visits for BAV-related diagnoses (Q23.0–Q23.1) is on a continuously increasing trend, and the proportion of new diagnoses in adults is high owing to the expanded spread of adult echocardiographic screening. Regular follow-up at a specialized cardiac center through Special Copayment Reduction (V147) registration is recommended.


5. Pathophysiology

The core pathophysiology of aortic valve insufficiency (regurgitation) in bicuspid aortic valve is left ventricular volume overload. When the aortic valve does not close completely in diastole and blood regurgitates into the left ventricle, the left ventricle must accommodate a total stroke volume equal to the normal output plus the regurgitant volume, so ventricular dilation and eccentric hypertrophy develop.

Initially, compensation is maintained by an increase in stroke volume through the Frank-Starling mechanism. However, when chronic volume overload persists, myocyte elongation (sarcomere addition in series) and collagen deposition progress, causing diastolic dysfunction. Eventually systolic function also declines, left ventricular systolic dysfunction appears, and heart failure symptoms develop. In this process, left ventricular dilation can secondarily cause mitral regurgitation (functional mitral regurgitation).

In BAV, the mechanism of aortopathy involves both a purely hemodynamic mechanism and an intrinsic medial abnormality. Hemodynamically, the eccentric high-velocity jet arising from the bicuspid valve repeatedly strikes a specific region of the ascending aorta, causing medial damage. As intrinsic mechanisms, smooth muscle cell dysfunction due to abnormalities of the NOTCH1/TGF-β signaling pathway and fibrillin-1 abnormalities have been reported.

In acute regurgitation (valve destruction after infective endocarditis, aortic dissection, etc.), there is no time for compensatory mechanisms to operate, so the left ventricle is suddenly exposed to a high preload, and a sharp rise in left ventricular end-diastolic pressure (LVEDP) → pulmonary edema → acute heart failure crisis occurs.


6. Symptoms

The clinical symptoms of aortic valve insufficiency (regurgitation) in bicuspid aortic valve vary according to the severity of regurgitation, the speed of onset (chronic vs acute), and the degree of left ventricular compensation.

Asymptomatic latent period: in mild to moderate chronic regurgitation, the asymptomatic state can persist for decades owing to the large-volume compensation of the left ventricle. While cardiac output remains normal, patients feel no discomfort in daily life. It is common for the first diagnosis in this period to be made in adulthood.

Early symptoms: the first symptom to appear in severe regurgitation is exercise intolerance (exertional dyspnea), with dyspnea occurring first during strenuous exercise. Patients tend at first to attribute this to age or reduced fitness, which sometimes delays diagnosis.

Advanced symptoms: as left ventricular failure progresses, symptoms of congestive heart failure appear, such as nocturnal orthopnea, paroxysmal nocturnal dyspnea (PND), fatigue, and lower limb edema. Anginal chest pain can occur, owing to increased myocardial oxygen demand from left ventricular hypertrophy and reduced coronary perfusion pressure from low diastolic blood pressure.

Acute aortic regurgitation: when acute severe regurgitation occurs owing to valve destruction from infective endocarditis, aortic dissection, or the like, the left ventricle is suddenly subjected to extreme volume overload, resulting in an emergency of acute pulmonary edema and cardiogenic shock.

Aortopathy-related symptoms: when aortic dissection occurs, sudden tearing pain in the back and chest develops, which is a life-threatening emergency.


7. Signs

The physical signs of aortic valve insufficiency in bicuspid aortic valve vary in proportion to the severity of regurgitation.

Auscultation findings: the characteristic finding is a high-pitched diastolic decrescendo murmur heard at the 3rd–4th intercostal space at the left sternal border. The murmur is heard better on expiration and with the patient leaning forward. In addition, the Austin Flint murmur heard at the apex is a low-pitched mid-diastolic murmur caused by the regurgitant jet striking the anterior mitral leaflet and is an indicator of severe regurgitation. In addition to aortic regurgitation, a systolic ejection murmur may be present.

Signs related to widened pulse pressure (hyperdynamic signs): in severe chronic regurgitation, systolic blood pressure rises and diastolic blood pressure falls, widening the pulse pressure. This produces a number of characteristic signs: ① Corrigan pulse (water hammer pulse): a pulse that rises rapidly and collapses abruptly ② de Musset sign: head bobbing in time with the heartbeat ③ Quincke pulse: pulsatile capillary flushing on pressure on the nail ④ Duroziez sign: systolic–diastolic double murmur on auscultation of the femoral artery ⑤ Hill sign: increased lower–upper limb blood pressure difference (normal <20 mmHg, severe regurgitation >60 mmHg).

Left ventricular findings: the apical impulse is displaced laterally to the left and is large and brisk (hyperdynamic).


8. Screening

Family screening: echocardiographic screening of first-degree relatives of BAV patients is recommended as Class I in the AHA/ACC guidelines. In BAV family studies, the detection rate of BAV in first-degree relatives is about 9–16%, making echocardiographic screening highly cost-effective.

Aortopathy screening: in patients already diagnosed with BAV, baseline measurement of the ascending aortic diameter (CT angiography or cardiac MRI) is recommended. When the aortic diameter is 40mm or more or it enlarges by 3mm or more per year, intensive follow-up (MRI/CT every 6–12 months) is needed.

Exercise stress testing: in asymptomatic patients with severe regurgitation, abnormal blood pressure response, symptom provocation, and functional impairment on exercise testing are assessed and used to decide the timing of intervention.

BNP/NT-proBNP: rises when left ventricular dysfunction begins, so it is used as an auxiliary marker during regular follow-up.

Pre-pregnancy evaluation: because pregnancy markedly increases the cardiovascular load in female BAV patients, the severity of regurgitation, left ventricular function, and aortic diameter should be checked and risk classified through cardiologist evaluation before pregnancy.


9. Diagnosis

Echocardiography: the standard for diagnosing bicuspid aortic valve and aortic regurgitation. Two-dimensional ultrasound assesses valve morphology (number of cusps, orientation of the fused commissure) and opening and closing motion, and color Doppler identifies the regurgitant jet. Regurgitation severity is quantified by the width of the regurgitant jet (vena contracta width ≥6mm = severe), regurgitant fraction (RF ≥50% = severe), effective regurgitant orifice area (EROA ≥0.3 cm² = severe), and regurgitant volume (RVol ≥60 mL/beat = severe). Left ventricular dilation (EDD >70mm, ESD >50mm) and ejection fraction (EF <50%) are important for determining surgical indications.

Cardiac MRI (CMR): measures left ventricular volume, function, and regurgitant fraction more precisely than echocardiography and is essential in patients with poor acoustic windows. Phase-contrast MRI directly calculates the aortic regurgitant fraction. Left ventricular myocardial fibrosis (late gadolinium enhancement) reflects irreversible myocardial damage and is associated with surgical prognosis.

Cardiac CT angiography: used for precise measurement of the ascending aortic diameter and preoperative planning (valve morphology, aortic anatomy). Valve calcification is quantified by the Agatston calcium score.

Cardiac catheterization: performed when noninvasive tests are insufficient or coexisting coronary artery disease is suspected, or for preoperative coronary angiography.


10. Treatment

Conservative treatment: in patients with mild to moderate regurgitation who are asymptomatic and have normal left ventricular function, regular echocardiographic follow-up is the rule. ACE inhibitors or ARBs were used in the past to delay progression of regurgitation, but because they have no effect on inhibiting progression of regurgitation in asymptomatic patients, routine administration is no longer recommended. Blood pressure control is important when hypertension is present.

Indications for surgical valve surgery (ACC/AHA 2020 guideline): ① symptomatic severe aortic regurgitation (Class I) ② asymptomatic severe regurgitation + resting EF ≤55% (Class I) ③ asymptomatic severe regurgitation + left ventricular dilation (EDD >65mm or ESD >50mm) (Class IIa) ④ moderate to severe regurgitation when undergoing other cardiac surgery (CABG, mitral valve surgery, etc.) (Class IIa).

Surgical methods: aortic valve repair is possible in some selected patients, and the correction method differs according to the cause of regurgitation (cusp prolapse, perforation, annular dilation). For valve replacement, a mechanical valve (requiring lifelong anticoagulation) or a bioprosthetic valve (no anticoagulation needed, limited durability) is chosen. When aortic dilation is present, concomitant aortic replacement (Bentall procedure, David valve-sparing aortic root replacement, etc.) is needed.

Surgical indications for aortopathy: prophylactic surgery is considered for an ascending aortic diameter ≥55mm (without risk factors), ≥50mm (with high-risk features or symptoms), or growth of ≥5mm per year.


11. Prognosis

The prognosis of patients with bicuspid aortic valve varies greatly depending on the treatment setting. With appropriate follow-up and timely surgery, life expectancy is nearly similar to that of the general population.

Natural history of asymptomatic patients: in asymptomatic patients with severe regurgitation, the annual risk of developing symptoms or left ventricular dysfunction is about 4–6%. The annual risk of sudden death is low at about 0.2%, but once left ventricular function has declined, the surgical prognosis also becomes poor, so timely intervention is important.

Postoperative prognosis: in patients operated on before symptoms develop or before left ventricular function declines, 10–15-year postoperative survival is good at 85–90% or more. When surgery is performed after left ventricular function has declined substantially, recovery of left ventricular function may be incomplete. When valve repair is successful, long-term results are better than with replacement.

Aortopathy-related prognosis: the annual risk of aortic dissection in BAV patients is 0.1–0.5%, and the risk increases sharply as the aortic diameter increases. After prophylactic aortic surgery, the risk of dissection is markedly reduced. Infective endocarditis is an important cause of long-term morbidity and emergency surgery in BAV patients.


12. Prevention

Prevention of infective endocarditis: BAV is a valve malformation at risk of endocarditis. In high-risk groups after valve replacement or with a history of endocarditis, prophylactic antibiotics are given before invasive oral procedures. General oral hygiene education and regular dental checkups are important.

Family screening: early diagnosis and management through echocardiographic screening of first-degree relatives of BAV patients.

Regular follow-up: mild regurgitation: ultrasound every 3–5 years; moderate: every 1–2 years; severe (asymptomatic): every 6–12 months. If the aortic diameter is 40mm or more, aortic size is followed by CT/MRI every year.

Blood pressure control: hypertension accelerates aortic dilation and progression of regurgitation, so active control is needed. ACE inhibitors, ARBs, and beta blockers are used in BAV patients with hypertension.

Exercise restriction: in severe regurgitation or an aortic diameter ≥50mm, strenuous high-intensity exercise (especially isometric exercise) is restricted. Moderate aerobic exercise is mostly permitted.

Pregnancy planning: before pregnancy, the severity of regurgitation, left ventricular function, and aortic diameter are checked through cardiologist evaluation, and pregnancy risk is classified. Surgery before pregnancy is recommended for patients with severe regurgitation, an aortic diameter ≥45mm, or left ventricular dysfunction.


13. References

  1. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med. 2014;370(20):1920-1929. DOI: 10.1056/NEJMra1207059. PMID: 24827036.

  2. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270-274. DOI: 10.1038/nature03940. PMID: 16025100.

  3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.

  4. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.

  5. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55(25):2789-2800. DOI: 10.1016/j.jacc.2009.12.068. PMID: 20579530.

  6. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306(10):1104-1112. DOI: 10.1001/jama.2011.1286. PMID: 21900135.

  7. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation. Eur J Echocardiogr. 2013;14(7):611-644. DOI: 10.1093/ehjci/jet105. PMID: 23733442.

  8. Detaint D, Sundt TM, Nkomo VT, et al. Aortic dilatation patterns and rates in adults with bicuspid aortic valves. Chest. 2014;146(3):792-799. DOI: 10.1378/chest.13-3023. PMID: 24939518.

  9. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900. DOI: 10.1016/S0735-1097(02)01886-7. PMID: 12084585.

  10. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA. 2008;300(11):1317-1325. DOI: 10.1001/jama.300.11.1317. PMID: 18799444.